tirzepatide compounding update pharmacies can resume making as FDA reconsiders shortage Ivím Health | Compounded Tirzepatide

Zepbound is FDA-approved and has demonstrated safety and effectiveness in clinical trials

The dual agonism appears to produce synergistic effects on weight loss, with clinical trials demonstrating up to ~21% body weight reduction at the 15 mg dose in people without diabetes, while weight loss is typically less in type 2 diabetes

It must be taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before eating or taking other medications

The survodutide comparison is worth noting here too, as survodutide is another glucagon-containing dual agonist that shows strong liver fat effects

Constipation: While some patients experience diarrhea, others may find that digestion slows too much, leading to constipation

More than half of the patients were GLP-1 RAexperienced